Related Experiment Video
Updated: Feb 18, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
Central Role of Transforming Growth Factor Type Beta 1 in Skeletal Muscle Dysfunctions: An Update on Therapeutic
Johanna Abrigo1,2, Felipe Simon2,3, Daniel Cabrera4,5
1Laboratory of Muscle Pathology, Fragility and Aging, Departamento de Ciencias Biologicas, Facultad de Ciencias Biologicas & Facultad de Medicina, Universidad Andres Bello, Santiago, Chile.
Abstract:
Among the soluble factors that regulate skeletal muscle function, Transforming Growth Factor type Beta 1 (TGF-β1) is one of the most studied. This factor inhibits myogenesis and regeneration by regulating the activity and function of satellite cells (SCs). Indeed, TGF-β has a central role in muscle pathologies in which there is development of fibrosis and/or atrophy of skeletal muscle. Thus, in this review we present the critical and recent antecedents regarding the mechanisms and cellular targets involved in the effects of TGF-β1 in the muscle, in pathological processes such as the inhibition of regeneration, fibrosis and atrophy. In addition, an update on the development of new strategies with therapeutic potential to inhibit the deleterious actions of TGF-β in skeletal muscle is discussed.
Insights
Transforming Growth Factor Beta 1 (TGF-β1) inhibits muscle regeneration and promotes fibrosis and atrophy. This review explores TGF-β1
Area of Science:
- Muscle physiology and pathology
- Cellular biology
- Regenerative medicine
Background:
- Transforming Growth Factor Beta 1 (TGF-β1) is a key regulator of skeletal muscle function.
- TGF-β1 plays a critical role in inhibiting myogenesis and regeneration.
- It is implicated in muscle pathologies characterized by fibrosis and atrophy.
Purpose of the Study:
- To review the mechanisms and cellular targets of TGF-β1 in skeletal muscle.
- To discuss the role of TGF-β1 in muscle regeneration inhibition, fibrosis, and atrophy.
- To provide an update on therapeutic strategies targeting TGF-β1's detrimental effects.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of cellular and molecular mechanisms.
- Synthesis of current therapeutic approaches.
Main Results:
- TGF-β1 signaling negatively impacts satellite cell activity and function.
- The factor is a central mediator in the development of muscle fibrosis and atrophy.
- Understanding these mechanisms is crucial for developing targeted therapies.
Conclusions:
- TGF-β1 is a significant detrimental factor in skeletal muscle pathologies.
- Inhibiting TGF-β1's deleterious actions holds therapeutic potential for muscle diseases.
- Further research into TGF-β1 inhibition strategies is warranted.
Related Concept Videos
TGF - β Signaling Pathway
Satellite Stem Cells and Muscular Dystrophy
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

